Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B I Rini

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trialsD Y C Heng, T K Choueiri, B I Rini, et al.
British Journal of Cancer|April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCJ J Ko, T K Choueiri, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaT K Choueiri, R J Motzer, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trialT K Choueiri, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialN M Tannir, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trialT K Choueiri, K Penkov, H Uemura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2021
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumP Grivas, A R Khaki, T M Wise-Draper, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trialsD Y C Heng, T K Choueiri, B I Rini, et al.
British Journal of Cancer|April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCJ J Ko, T K Choueiri, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaT K Choueiri, R J Motzer, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trialT K Choueiri, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialN M Tannir, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trialT K Choueiri, K Penkov, H Uemura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2021
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumP Grivas, A R Khaki, T M Wise-Draper, et al.
Pageof 4